
Sentinel BioTherapeutics launches at 2025 ASCO Annual Meeting
Biotech venture creation studio RBL has launched Sentinel BioTherapeutics, a spin-out from Rice University, at the 2025 ASCO Annual Meeting. This is RBL's first company spin-out since its formation in October 2024 and positions Sentinel to begin preparations ahead of the next phase of clinical development for its lead cancer… Read More
